This system can deliver insulin in two different modes: the AHCL automatic mode (SmartGuard Mode®, Medtronic, Northridge, CA, USA), approved for use in children with T1DM above the age of 7 years and a total daily insulin dose (TDD) of at least 8 U/day, and the manual mode, which delivers user-programmed insulin maintaining only a predictive low-glucose suspend (PLGS) function, able to automatically suspend insulin delivery in case of predicted hypoglycaemia [8]. This evidence concerns the gene INS and type 1 diabetes mellitus.